As of press release, the stock had risen more than 216% to $0.806
The Zhitong Finance App learned that on Tuesday, Mangoceuticals (MGRX.US) stock price rose. As of press release, the stock had risen more than 216% to $0.806. The company announced that it will launch oral versions of GLP-1 weight loss drugs semaglutide and tirzepatide, with a total market capitalization of over $21.1 million.
The injectable version of Semaglutide is sold by NVO.US (NVO.US) under the Wegovy brand, while the injectable version of Tirzepatide is sold by LLY.US (LLY.US) under the Zepbound brand.
Mangoceuticals said these oral soluble tablets will be available through its telemedicine platform beginning in the third quarter. Oral Semaglutide will be sold under the “Slim” brand at a monthly cost of $299; while oral Tirzepatide will be sold under the “Trim” brand at a monthly cost of $399.